

Matt Mannelly, President & CEO Ron Lombardi, CFO

Safe Harbor Disclosure

During this call statements may be made by management of their beliefs and expectations as to the Company's future operating results. Statements of management's expectations of what might occur with respect to future operating results are what is known as forward-looking statements. All forward-looking statements involve risks and uncertainties, which in many cases are beyond the control of the Company and may cause actual results to differ materially from management's expectations. Additional information concerning the factors that might cause actual results to differ from management's expectations is contained in the Company's annual and quarterly reports that it files with the US Securities & Exchange Commission.





































Q3 Key Business Highlights



Strong overall revenue growth in Q3 driven by BOTH core OTC and Blacksmith acquisition in addition to continued strong free cash flow.



Growth strategy for core OTC franchise is underway

- Increased investment in A&P and new product strategy driving revenue growth
- Core OTC consumption growth of 26.5% in Q3; significantly exceeding category (1.0%)



Focused M&A strategy yielding results and playing expected role

- Successfully integrating Blacksmith Brands
- Announced acquisition of Dramamine®, a number one OTC brand



Profitability impacted by appropriate strategic investment in core brands and costs relating to Blacksmith Brands acquisition



FY2011 investment and brand-building, positioning business for FY2012 and beyond

Comments exclude the adjustments detailed on page 18





































OTC Portfolio with 8 Core Brands Following Blacksmith Transaction







6 OTC Brands Greater Than \$20 Million Net Sales


































Core OTC Business Represents 66% of the Portfolio and 90% of the OTC Segment









Note: Net Sales pro forma for Cutex divestiture





































Increased A&P Support of Core OTC Franchise Focused on Innovative Campaigns and New Product Launches



Clear eyes_®





A&P Strategy



- Ben Stein advertising
- Digital marketing



Lozenge TV campaign





New **Products**










Q3 Consumption

Brand Category









































Commitment to Equity Building Brand Support of Acquired Brands





- National TV campaign (11/15)
- Digital marketing





- Radio campaign
- Digital marketing
- On-Mountain sampling; FSI's





- Bonus packs
- FSI's










































A&P Spending Behind Core OTC Brands Resulted in...

Core OTC Q3 A&P Spending FY2010 (% of Net Revenue) FY2011 (% of Net Revenue) 33.8%












































... The Core OTC Portfolio Significantly Outperforming the Category...











Source: Latest 12-week IRI FDMx dollar sales for the period ending December 26, 2010






































...with Consumption Trends Accelerating in **Recent Periods**





Source: Latest 12-week IRI FDMx dollar sales for the period ending December 26, 2010










































Household Product Segment Maintained Share Despite Soft Category Trends in Q3

Q3 Consumption Trends





Q3 Consumption Dynamics

- Consumption trends for household cleansers have been soft in Q3
- Comet_® cleanser abrasives are out-performing the category
 - Abrasives represent 55% of Prestige's household segment consumption
 - Abrasives gained 1.3% points share in Q3
- Comet sprays were impacted by new competitive introductions supported by promotional activity
- Prestige is pursuing new line extensions and packaging options for FY2012 and gaining incremental channel distribution

Source: IRI FDMx sales for the latest 12-week period ending December 26, 2010













































Blacksmith Brands Integration on Track



Marketing support and structure 100% integrated



Advertising campaigns began in November with POS results showing solid responses



Prestige sales force is up to speed and managing brands with brokers/outside sales force while we determine best long term structure



Back room integration:

- Purchasing 100% integrated
- Warehousing and systems integration scheduled to consolidate by April 1st



No disruptions in shipments or receivables during transition



Appropriate marketing investment to support long-term sustainable growth



































Successful Acquisition of Dramamine® Brand from McNeil-PPC, Inc.



On January 6, 2011, Prestige completed the acquisition of the Dramamine® brand in the U.S.



Effective purchase price of \$62 million including the present value of tax attributes of approximately \$14 million



Dramamine is the #1 Brand in the OTC motion sickness category with an estimated market share of 32%

Dramamine is nearly 3x larger than its closest branded competitor



Represents another strategic acquisition in core OTC franchise of an attractive, growing brand

Dramamine consumption grew 6.6% (latest 52-week)



Company expects to quickly and smoothly integrate Dramamine into the portfolio

Straightforward business with three SKUs



Acquisition expected to be accretive in FY2012

Source: IRI FDMx dollar sales for the period ending December 26, 2010








































Continued Focus on Growth of the Core OTC Business with the Dramamine® Acquisition









Note: Net Sales pro forma for Cutex divestiture





































Introduction to Financial Results



Strong top-line revenue growth for Prestige's core OTC brands and Blacksmith Brands



Significant A&P investment behind core OTC brands and Blacksmith Brands acquisition driving revenue growth trends



Net Income and EPS growth over FY2010 Q3



Solid Q3 performance includes investments for growth

Comments exclude the adjustments detailed on page 18

































Q3 Consolidated Financial Summary

Summary P&L

	Q3						
	FY2011	FY2010	% Change				
Net Revenue	\$ 90.6	\$ 73.8	22.7%				
Adjusted Gross Profit ⁽¹⁾	47.6	39.1	21.6%				
% Margin	<i>52.5%</i>	<i>53.0%</i>					
A&P	13.0	6.0	117.5%				
% of Net Revenue	<i>14.4%</i>	<i>8.1%</i>					
Adjusted G&A ⁽¹⁾	8.5	7.3	16.4%				
% of Net Revenue	<i>9.4%</i>	9.9%					
D&A	2.5	2.5	0.5%				
% of Net Revenue	<i>2.8%</i>	<i>3.4</i> %					
Adjusted Operating Income ⁽¹⁾ % Margin	23.5 <i>25</i> .9%	23.3 <i>31.6%</i>	0.8%				
Adjusted Net Income ⁽¹⁾	\$ 10.3	\$ 10.0	_ 3.0%				
Adjusted Earnings Per Share ⁽¹⁾	\$ 0.21	7	3.2%				
Earnings Per Share - As Reported	\$ 0.04		(79.2%)				
Adjusted EBITDA ⁽¹⁾	26.0	25.8	0.8%				
% Margin	<i>28.7%</i>	<i>35.0%</i>					

Comments

- Net revenue grew by \$16.8 million or 22.7% over year ago, driven primarily by core OTC segment
 - 2.1% Growth excluding Blacksmith Brands
- Significant investment in A&P driving revenue growth to support core OTC franchise and acquired Blacksmith **Brands**
- G&A increase resulting from Blacksmith Brands acquisition and YTD timing
- Adjusted Net Income increased 3.0% after increased strategic A&P investment

Dollars in millions

(1) Excludes adjustments detailed on page 18









































December YTD Consolidated Financial Summary

Summary P&L

	December YTD							
	FY2011	FY2010	% Change					
Net Revenue	\$ 240.1	\$ 222.7	7.8%					
Adjusted Gross Profit ⁽¹⁾ % Margin	128.1 <i>53.3%</i>							
A&P % of Net Revenue	28.8 <i>12.0%</i>							
Adjusted G&A ⁽¹⁾ % of Net Revenue	24.0 <i>10.0%</i>							
D&A % of Net Revenue	7.3 <i>3.1%</i>	7.4 <i>3.3%</i>	(0.9%)					
Adjusted Operating Income ⁽¹⁾ % Margin	68.0 28.3%	60.7 <i>27.3%</i>	12.0%					
Adjusted Net Income ⁽¹⁾	\$ 30.9	\$ 26.3	17.6%					
Adjusted Earnings Per Share ⁽¹⁾ Earnings Per Share - As Reported	\$ 0.62 \$ 0.46	\$ 0.53 \$ 0.58	17.4% (20.9%)					
Adjusted EBITDA ⁽¹⁾ % Margin	75.3 31.4%	68.1 <i>30.6%</i>	10.6%					

Comments

- Net revenue grew by \$17.5million or 7.8% over year ago, driven primarily by the core OTC segment
 - 1% Growth excluding Blacksmith Brands
- Adjusted G&A savings of \$2.1 million from prior year
- Adjusted Operating Income grew by \$7.3 million or 12.0%, and an improved Operating Margin of 28.3%
- Strong Adjusted Net Income growth of 17.6%

Dollars in millions

(1) Excludes adjustments detailed on page 18







































Q3 Net Income and EPS Reconciliation

	<u></u>			December 11D				
	Net	Income		EPS	Net	<u>Income</u>		EPS
Q3 FY2011 Adjusted for One-time Items		10.3	\$	0.21	\$	30.9	\$	0.62
One-time Adjustments								
Incremental Interest Expense to Finance Dramamine®		(0.8)		(0.02)		(0.8)		(0.02)
Inventory Step-up Associated with Blacksmith Purchase Price Allocation		(3.5)		(0.07)		(3.5)		(0.07)
Blacksmith Acquisition Costs								•
Transaction Fees & Expenses (M&A, Legal, Other)		(3.4)		(0.07)		(3.4)		(0.07)
Severance		(3.0)		(0.06)		(3.0)		(0.06)
Lease Termination		(0.6)		(0.01)		(0.6)		(0.01)
Tax Impact of One-time Adjustments		3.1		0.06		3.1		0.06
Q3 FY2011 As Reported	\$	2.2	\$	0.04	\$	22.8	\$	0.46

Dollars in millions, except per share amounts





































Q3 Segment Financial Summary

					Q3	1,000	
		OTC ⁽¹⁾		Household Cleaning		Consolidated	
Net Revenue	FY2011 FY2010	\$	67.5 46.6	\$	23.1 27.3	\$	90.6 73.8
	% Change		44.9%		(15.1%)		22.7%
Gross Profit	FY2011 ⁽²⁾ % Margin FY2010 % Margin % Change		40.2 59.6% 29.4 63.1% 36.7%		7.4 31.9% 9.8 35.9% (24.6%)		47.6 52.5% 39.1 53.0% 21.6%
A&P Spending	FY2011 FY2010 % Change		11.8 5.2 <i>129.5</i> %		1.2 0.9 <i>37.7%</i>		13.0 6.0 <i>117.5%</i>
Contribution	FY2011 ⁽²⁾ FY2010		28.3 24.2		6.2 8.9		34.5 33.1
	% Change		17.0%		(30.7%)		4.3%

- OTC segment revenue grew 44.9% with core OTC up 12.3% (excluding Blacksmith) in Q3 behind dedicated A&P support and improving Cough/Cold season versus year ago
- Household revenue down 15.1%; soft consumption, competitive entries, program timing
- Gross margin in line with expectations given Blacksmith acquisition
- A&P increase as previously communicated; Blacksmith Brand acquisition, core OTC investment and timing

Dollars in millions

- (1) FY2011 includes Blacksmith Brands
- (2) Excludes adjustments detailed on page 18





































Continued Strong Cash Flow from Operations

	FY2011						
		Q3					
Net Income	\$	2.2	\$	22.8			
Non-cash operating items		3.5		17.6			
Working Capital		10.8		17.2			
Other		2.3		4.1			
Cash Flow from Operations	\$	18.8	\$	61.7			

Dollars in millions



































Well Positioned Heading into FY2012



Retail environment showing signs of improvement



Continued focused A&P support behind core OTC brands

- Investment to support continued growth for PediaCare, Little Remedies, Chloraseptic® and Luden's® in heart of Cough/Cold season
- Increased A&P support for Clear Eyes® to maintain momentum



Comet_® focused on winning at retail; increased usage occasions



Working to complete integration of Blacksmith and Dramamine® brands



Q4: Stepping stone for FY12

- Revenue growth momentum for core OTC
- Continued appropriate A&P investment to fuel current and future growth
- Additional charges associated with Blacksmith and Dramamine acquisitions





































Q3 Key Business Summary



Strong overall revenue growth in Q3 driven by BOTH core OTC and Blacksmith acquisition in addition to continued strong free cash flow.



Growth strategy for core OTC franchise is underway

- Increased investment in A&P and new product strategy driving revenue growth
- Core OTC consumption growth of 26.5% in Q3; significantly exceeding category (1.0%)



Focused M&A strategy yielding results and playing expected role

- Successfully integrating Blacksmith Brands
- Announced acquisition of Dramamine®, a number one OTC brand



Profitability impacted by appropriate strategic investment in core brands and costs relating to Blacksmith Brands acquisition



FY2011 investment and brand-building, positioning business for FY2012 and beyond

Comments exclude the adjustments detailed on page 18







































